<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34232731</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>19</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections.</ArticleTitle><Pagination><StartPage>e0061921</StartPage><MedlinePgn>e0061921</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00619-21</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00619-21</ELocationID><Abstract><AbstractText>Although transmission of Zika virus (ZIKV) in the Americas has greatly declined since late 2017, recent reports of reduced risks of symptomatic Zika by prior dengue virus (DENV) infection and increased risks of severe dengue disease by previous ZIKV or DENV infection underscore a critical need for serological tests that can discriminate past ZIKV, DENV, and/or other flavivirus infections and improve our understanding of the immune interactions between these viruses and vaccine strategy in endemic regions. As serological tests for ZIKV primarily focus on envelope (E) and nonstructural protein 1 (NS1), antibodies to other ZIKV proteins have not been explored. Here, we employed Western blot analysis using antigens of 6 flaviviruses from 3 serocomplexes to investigate antibody responses following reverse transcription-PCR (RT-PCR)-confirmed ZIKV infection. Panels of 20 primary ZIKV and 20 ZIKV with previous DENV infection recognized E proteins of all 6 flaviviruses and the NS1 protein of ZIKV with some cross-reactivity to DENV. While the primary ZIKV panel recognized only the premembrane (prM) protein of ZIKV, the ZIKV with previous DENV panel recognized both ZIKV and DENV prM proteins. Analysis of antibody responses following 42 DENV and 18 West Nile virus infections revealed similar patterns of recognition by anti-E and anti-NS1 antibodies, whereas both panels recognized the prM protein of the homologous serocomplex but not others. The specificity was further supported by analysis of sequential samples. Together, these findings suggest that anti-prM antibody is a flavivirus serocomplex-specific marker and can be used to delineate current and past flavivirus infections in endemic areas. <b>IMPORTANCE</b> Despite a decline in Zika virus (ZIKV) transmission since late 2017, questions regarding its surveillance, potential reemergence, and interactions with other flaviviruses in regions where it is endemic remain unanswered. Recent studies have reported reduced risks of symptomatic Zika by prior dengue virus (DENV) infection and increased risks of severe dengue disease by previous ZIKV or DENV infection, highlighting a need for better serological tests to discriminate past ZIKV, DENV, and/or other flavivirus infections and improved understanding of the immune interactions and vaccine strategy for these viruses. As most serological tests for ZIKV focused on envelope and nonstructural protein 1, antibodies to other ZIKV proteins, including potentially specific antibodies, remain understudied. We employed Western blot analysis using antigens of 6 flaviviruses to study antibody responses following well-documented ZIKV, DENV, and West Nile virus infections and identified anti-premembrane antibody as a flavivirus serocomplex-specific marker to delineate current and past flavivirus infections in areas where flaviviruses are endemic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hsieh</LastName><ForeName>Szu-Chia</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tsai</LastName><ForeName>Wen-Yang</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Jih-Jin</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Tropical Medicine Center, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Mars</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Graham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busch</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanteri</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stramer</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>American Red Crossgrid.281926.6 Scientific Support Office, Gaithersburg, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balmaseda</LastName><ForeName>Angel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Virology Laboratory, National Center for Diagnosis and Reference, Ministry of Health, Managua, Nicaragua.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sustainable Sciences Institute, Managua, Nicaragua.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Vaccinology, School of Public Health, University of California-Berkeley, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei-Kung</ForeName><Initials>WK</Initials><Identifier Source="ORCID">0000-0002-6670-4663</Identifier><AffiliationInfo><Affiliation>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN268201100001I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NHRI-110A1-MRCO-03212101</GrantID><Agency>National Health Research Institute, Taiwan</Agency><Country/></Grant><Grant><GrantID>R21 AI135292</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 GM114737</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 AI065359</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI118610</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30GM114737</GrantID><Agency>HHS | NIH | National Institute of General Medical Sciences (NIGMS)</Agency><Country/></Grant><Grant><GrantID>R01 AI099631</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2HL101632</GrantID><Agency>HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)</Agency><Country/></Grant><Grant><GrantID>HHSN268201100001C</GrantID><Acronym>WH</Acronym><Agency>WHI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 HL101632</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AI106695</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AI149502-01</GrantID><Agency>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country/></Grant><Grant><GrantID>R01 AI149502</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>19CON-95451</GrantID><Agency>Hawaii Community Foundation (HCF)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000621601">NS1 protein, zika virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C074932">prM protein, Flavivirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014901" MajorTopicYN="N">West Nile Fever</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014902" MajorTopicYN="N">West Nile virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071244" MajorTopicYN="N">Zika Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071243" MajorTopicYN="N">Zika Virus Infection</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Zika virus</Keyword><Keyword MajorTopicYN="N">antibody</Keyword><Keyword MajorTopicYN="N">flavivirus</Keyword><Keyword MajorTopicYN="N">premembrane protein</Keyword><Keyword MajorTopicYN="N">serodiagnosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>7</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34232731</ArticleId><ArticleId IdType="pmc">PMC8428386</ArticleId><ArticleId IdType="doi">10.1128/JVI.00619-21</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dick GW, Kitchen SF, Haddow AJ. 1952. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 46:509&#x2013;520. doi:10.1016/0035-9203(52)90042-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0035-9203(52)90042-4</ArticleId><ArticleId IdType="pubmed">12995440</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson DI. 1964. Zika virus infection in man. Trans R Soc Trop Med Hyg 58:335&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">14175744</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikan N, Smith DR. 2016. Zika virus: history of a newly emerging arbovirus. Lancet Infect Dis 16:e119&#x2013;e126. doi:10.1016/S1473-3099(16)30010-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(16)30010-X</ArticleId><ArticleId IdType="pubmed">27282424</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, Pretrick M, Marfel M, Holzbauer S, Dubray C, Guillaumot L, Griggs A, Bel M, Lambert AJ, Laven J, Kosoy O, Panella A, Biggerstaff BJ, Fischer M, Hayes EB. 2009. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 360:2536&#x2013;2543. doi:10.1056/NEJMoa0805715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0805715</ArticleId><ArticleId IdType="pubmed">19516034</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao-Lormeau VM, Roche C, Teissier A, Robin E, Berry ALT, Mallet HP, Sall AA, Musso D. 2014. Zika virus, French Polynesia, South Pacific, 2013. Emerg Infect Dis 20:1085&#x2013;1086. doi:10.3201/eid2006.140138.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2006.140138</ArticleId><ArticleId IdType="pmc">PMC4036769</ArticleId><ArticleId IdType="pubmed">24856001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lessler J, Chaisson LH, Kucirka LM, Bi Q, Grantz K, Salje H, Carcelen AC, Ott CT, Sheffield JS, Ferguson NM, Cummings DA, Metcalf CJ, Rodriguez-Barraquer I. 2016. Assessing the global threat from Zika virus. Science 353:aaf8160. doi:10.1126/science.aaf8160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf8160</ArticleId><ArticleId IdType="pmc">PMC5467639</ArticleId><ArticleId IdType="pubmed">27417495</ArticleId></ArticleIdList></Reference><Reference><Citation>Musso D, Ko AI, Baud D. 2019. Zika virus infection - after the pandemic. N Engl J Med 381:1444&#x2013;1457. doi:10.1056/NEJMra1808246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1808246</ArticleId><ArticleId IdType="pubmed">31597021</ArticleId></ArticleIdList></Reference><Reference><Citation>PAHO. 2017. Regional Zika epidemiological update (Americas). PAHO, Washington, DC. http://www.paho.org/hq/index.php?option=com_content&amp;view=article&amp;id=11599&amp;Itemid=41691&amp;lang=en. Accessed 1 December 2020.</Citation></Reference><Reference><Citation>Krauer F, Riesen M, Reveiz L, Oladapo OT, Mart&#xed;nez-Vega R, Porgo TV, Haefliger A, Broutet NJ, Low N, WHO Zika Causality Working Group. 2017. Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barr&#xe9; syndrome: systematic review. PLoS Med 14:e1002203. doi:10.1371/journal.pmed.1002203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002203</ArticleId><ArticleId IdType="pmc">PMC5207634</ArticleId><ArticleId IdType="pubmed">28045901</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliota MT, Bassit L, Bradrick SS, Cox B, Garcia-Blanco MA, Gavegnano C, Friedrich TC, Golos TG, Griffin DE, Haddow AD, Kallas EG, Kitron U, Lecuit M, Magnani DM, Marrs C, Mercer N, McSweegan E, Ng LFP, O'Connor DH, Osorio JE, Ribeiro GS, Ricciardi M, Rossi SL, Saade G, Schinazi RF, Schott-Lerner GO, Shan C, Shi PY, Watkins DI, Vasilakis N, Weaver SC. 2017. Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network. Antiviral Res 144:223&#x2013;246. doi:10.1016/j.antiviral.2017.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.06.001</ArticleId><ArticleId IdType="pmc">PMC5920658</ArticleId><ArticleId IdType="pubmed">28595824</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Diamond MS. 2013. Flaviviruses, p 747&#x2013;794. In Knipe DM, Howley PM (ed), Fields virology, 6th ed. Lippincott William &amp; Wilkins, Philadelphia, PA.</Citation></Reference><Reference><Citation>Abbink P, Stephenson KE, Barouch DH. 2018. Zika virus vaccines. Nat Rev Microbiol 16:594&#x2013;600. doi:10.1038/s41579-018-0039-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0039-7</ArticleId><ArticleId IdType="pmc">PMC6162149</ArticleId><ArticleId IdType="pubmed">29921914</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirohi D, Chen Z, Sun L, Klose T, Pierson TC, Rossmann MG, Kuhn RJ. 2016. The 3.8 &#xc5; resolution cryo-EM structure of Zika virus. Science 352:467&#x2013;470. doi:10.1126/science.aaf5316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf5316</ArticleId><ArticleId IdType="pmc">PMC4845755</ArticleId><ArticleId IdType="pubmed">27033547</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostyuchenko VA, Lim EX, Zhang S, Fibriansah G, Ng TS, Ooi JS, Shi J, Lok SM. 2016. Structure of the thermally stable Zika virus. Nature 533:425&#x2013;428. doi:10.1038/nature17994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature17994</ArticleId><ArticleId IdType="pubmed">27093288</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SA, Nivarthi UK, de Alwis R, Kose N, Sapparapu G, Bombardi R, Kahle KM, Pfaff JM, Lieberman S, Doranz BJ, de Silva AM, Crowe JE, Jr.. 2016. Dengue virus prM-specific human monoclonal antibodies with virus replication-enhancing properties recognize a single immunodominant antigenic site. J Virol 90:780&#x2013;789. doi:10.1128/JVI.01805-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01805-15</ArticleId><ArticleId IdType="pmc">PMC4702676</ArticleId><ArticleId IdType="pubmed">26512092</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton C. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745&#x2013;748. doi:10.1126/science.1185181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1185181</ArticleId><ArticleId IdType="pmc">PMC3837288</ArticleId><ArticleId IdType="pubmed">20448183</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA, Crowe JE, Wang WK, Harris E, de Silva AM. 2014. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog 10:e1004386. doi:10.1371/journal.ppat.1004386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004386</ArticleId><ArticleId IdType="pmc">PMC4183589</ArticleId><ArticleId IdType="pubmed">25275316</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller DA, Young PR. 2013. The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker. Antiviral Res 98:192&#x2013;208. doi:10.1016/j.antiviral.2013.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.03.008</ArticleId><ArticleId IdType="pubmed">23523765</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasner DR, Puerta-Guardo H, Beatty PR, Harris E. 2018. The good, the bad, and the shocking: the multiple roles of dengue virus nonstructural protein 1 in protection and pathogenesis. Annu Rev Virol 5:227&#x2013;253. doi:10.1146/annurev-virology-101416-041848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-101416-041848</ArticleId><ArticleId IdType="pmc">PMC6311996</ArticleId><ArticleId IdType="pubmed">30044715</ArticleId></ArticleIdList></Reference><Reference><Citation>Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP, Liu L, Hume DA, Stacey KJ, Young PR. 2015. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med 7:304ra142. doi:10.1126/scitranslmed.aaa3863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaa3863</ArticleId><ArticleId IdType="pubmed">26355031</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty PR, Puerta-Guardo H, Killingbeck SS, Glasner DR, Hopkins K, Harris E. 2015. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci Transl Med 7:304ra141. doi:10.1126/scitranslmed.aaa3787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaa3787</ArticleId><ArticleId IdType="pubmed">26355030</ArticleId></ArticleIdList></Reference><Reference><Citation>Puerta-Guardo H, Tabata T, Petitt M, Dimitrova M, Glasner DR, Pereira L, Harris E. 2020. Zika virus nonstructural protein 1 disrupts glycosaminoglycans and causes permeability in developing human placentas. J Infect Dis 221:313&#x2013;324. doi:10.1093/infdis/jiz331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz331</ArticleId><ArticleId IdType="pmc">PMC6936002</ArticleId><ArticleId IdType="pubmed">31250000</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, Sakuntabhai A, Cao-Lormeau VM, Malasit P, Rey FA, Mongkolsapaya J, Screaton GR. 2016. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat Immunol 17:1102&#x2013;1108. doi:10.1038/ni.3515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3515</ArticleId><ArticleId IdType="pmc">PMC4994874</ArticleId><ArticleId IdType="pubmed">27339099</ArticleId></ArticleIdList></Reference><Reference><Citation>Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, Pattanapanyasat K, Chokephaibulkit K, Mulligan MJ, Wilson PC, Ahmed R, Suthar MS, Wrammert J. 2016. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A 113:7852&#x2013;7857. doi:10.1073/pnas.1607931113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1607931113</ArticleId><ArticleId IdType="pmc">PMC4948328</ArticleId><ArticleId IdType="pubmed">27354515</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA, Nachbagauer R, Foster GA, Krysztof D, Tortorella D, Stramer SL, Garc&#xed;a-Sastre A, Krammer F, Lim JK. 2017. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science 356:175&#x2013;180. doi:10.1126/science.aal4365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aal4365</ArticleId><ArticleId IdType="pmc">PMC5714274</ArticleId><ArticleId IdType="pubmed">28360135</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathore APS, Saron WAA, Lim T, Jahan N, St John AL. 2019. Maternal immunity and antibodies to dengue virus promote infection and Zika virus-induced microcephaly in fetuses. Sci Adv 5:eaav3208. doi:10.1126/sciadv.aav3208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aav3208</ArticleId><ArticleId IdType="pmc">PMC6392794</ArticleId><ArticleId IdType="pubmed">30820456</ArticleId></ArticleIdList></Reference><Reference><Citation>McCracken MK, Gromowski GD, Friberg HL, Lin X, Abbink P, De La Barrera R, Eckles KH, Garver LS, Boyd M, Jetton D, Barouch DH, Wise MC, Lewis BS, Currier JR, Modjarrad K, Milazzo M, Liu M, Mullins AB, Putnak JR, Michael NL, Jarman RG, Thomas SJ. 2017. Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques. PLoS Pathog 13:e1006487. doi:10.1371/journal.ppat.1006487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006487</ArticleId><ArticleId IdType="pmc">PMC5542404</ArticleId><ArticleId IdType="pubmed">28771605</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantoja P, P&#xe9;rez-Guzm&#xe1;n EX, Rodr&#xed;guez IV, White LJ, Gonz&#xe1;lez O, Serrano C, Giavedoni L, Hodara V, Cruz L, Arana T, Mart&#xed;nez MI, Hassert MA, Brien JD, Pinto AK, de Silva A, Sariol CA. 2017. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat Commun 8:15674. doi:10.1038/ncomms15674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15674</ArticleId><ArticleId IdType="pmc">PMC5490051</ArticleId><ArticleId IdType="pubmed">28643775</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. 2017. Biologic evidence required for Zika disease enhancement by dengue antibodies. Emerg Infect Dis 23:569&#x2013;573. doi:10.3201/eid2304.161879.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2304.161879</ArticleId><ArticleId IdType="pmc">PMC5367429</ArticleId><ArticleId IdType="pubmed">28322690</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Barraquer I, Costa F, Nascimento EJM, Nery N, Jr, Castanha PMS, Sacramento GA, Cruz J, Carvalho M, De Olivera D, Hagan JE, Adhikarla H, Wunder EA, Jr, Co&#xea;lho DF, Azar SR, Rossi SL, Vasilakis N, Weaver SC, Ribeiro GS, Balmaseda A, Harris E, Nogueira ML, Reis MG, Marques ETA, Cummings DAT, Ko AI. 2019. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science 363:607&#x2013;610. doi:10.1126/science.aav6618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav6618</ArticleId><ArticleId IdType="pmc">PMC8221194</ArticleId><ArticleId IdType="pubmed">30733412</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon A, Gresh L, Ojeda S, Katzelnick LC, Sanchez N, Mercado JC, Chowell G, Lopez B, Elizondo D, Coloma J, Burger-Calderon R, Kuan G, Balmaseda A, Harris E. 2019. Prior dengue virus infection and risk of Zika: a pediatric cohort in Nicaragua. PLoS Med 16:e1002726. doi:10.1371/journal.pmed.1002726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002726</ArticleId><ArticleId IdType="pmc">PMC6342296</ArticleId><ArticleId IdType="pubmed">30668565</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzelnick LC, Narvaez C, Arguello S, Lopez Mercado B, Collado D, Ampie O, Elizondo D, Miranda T, Bustos Carillo F, Mercado JC, Latta K, Schiller A, Segovia-Chumbez B, Ojeda S, Sanchez N, Plazaola M, Coloma J, Halloran ME, Premkumar L, Gordon A, Narvaez F, de Silva AM, Kuan G, Balmaseda A, Harris E. 2020. Zika virus infection enhances future risk of severe dengue disease. Science 369:1123&#x2013;1128. doi:10.1126/science.abb6143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb6143</ArticleId><ArticleId IdType="pmc">PMC8274975</ArticleId><ArticleId IdType="pubmed">32855339</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin DA, Muth DA, Brown T, Johnson AJ, Karabatsos N, Roehrig JT. 2000. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol 38:1823&#x2013;1826. doi:10.1128/JCM.38.5.1823-1826.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.38.5.1823-1826.2000</ArticleId><ArticleId IdType="pmc">PMC86599</ArticleId><ArticleId IdType="pubmed">10790107</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AJ, Martin DA, Karabatsos N, Roehrig JT. 2000. Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay. J Clin Microbiol 38:1827&#x2013;1831. doi:10.1128/JCM.38.5.1827-1831.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.38.5.1827-1831.2000</ArticleId><ArticleId IdType="pmc">PMC86600</ArticleId><ArticleId IdType="pubmed">10790108</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. 2018. Guidance for U.S. laboratories testing for Zika virus infection. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/zika/laboratories/lab-guidance.html.</Citation></Reference><Reference><Citation>Lustig Y, Zelena H, Venturi G, Van Esbroeck M, Rothe C, Perret C, Koren R, Katz-Likvornik S, Mendelson E, Schwartz E. 2017. Sensitivity and kinetics of an NS1-based Zika virus enzyme-linked immunosorbent assay in Zika virus-infected travelers from Israel, the Czech Republic, Italy, Belgium, Germany, and Chile. J Clin Microbiol 55:1894&#x2013;1901. doi:10.1128/JCM.00346-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00346-17</ArticleId><ArticleId IdType="pmc">PMC5442546</ArticleId><ArticleId IdType="pubmed">28381608</ArticleId></ArticleIdList></Reference><Reference><Citation>Safronetz D, Sloan A, Stein DR, Mendoza E, Barairo N, Ranadheera C, Scharikow L, Holloway K, Robinson A, Traykova-Andonova M, Makowski K, Dimitrova K, Giles E, Hiebert J, Mogk R, Beddome S, Drebot M. 2017. Evaluation of 5 commercially available Zika virus immunoassays. Emerg Infect Dis 23:1577&#x2013;1580. doi:10.3201/eid2309.162043.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2309.162043</ArticleId><ArticleId IdType="pmc">PMC5572859</ArticleId><ArticleId IdType="pubmed">28665268</ArticleId></ArticleIdList></Reference><Reference><Citation>Balmaseda A, Zambrana JV, Collado D, Garc&#xed;a N, Sabor&#xed;o S, Elizondo D, Mercado JC, Gonzalez K, Cerpas C, Nu&#xf1;ez A, Corti D, Waggoner JJ, Kuan G, Burger-Calderon R, Harris E. 2018. Comparison of four serological methods and two reverse transcription-PCR assays for diagnosis and surveillance of Zika virus infection. J Clin Microbiol 56:e01785-17. doi:10.1128/JCM.01785-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01785-17</ArticleId><ArticleId IdType="pmc">PMC5824050</ArticleId><ArticleId IdType="pubmed">29305550</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai WY, Youn HH, Brites C, Tsai JJ, Tyson J, Pedroso C, Drexler JF, Stone M, Simmons G, Busch MP, Lanteri M, Stramer SL, Balmaseda A, Harris E, Wang WK. 2017. Distinguishing secondary dengue virus infection from Zika virus infection with previous dengue by combination of three simple serological tests. Clin Infect Dis 65:1829&#x2013;1836. doi:10.1093/cid/cix672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cix672</ArticleId><ArticleId IdType="pmc">PMC5850648</ArticleId><ArticleId IdType="pubmed">29020159</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyson J, Tsai WY, Tsai JJ, Brites C, M&#xe4;ssg&#xe5;rd L, Youn HH, Pedroso C, Drexler JF, Stramer SL, Balmaseda A, Harris E, Wang WK. 2019. Combination of non-structural protein 1-based enzyme-linked immunosorbent assays can detect and distinguish various dengue virus and Zika virus infections. J Clin Microbiol 57:e01464-18. doi:10.1128/JCM.01464-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01464-18</ArticleId><ArticleId IdType="pmc">PMC6355536</ArticleId><ArticleId IdType="pubmed">30429254</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyson J, Tsai WY, Tsai JJ, M&#xe4;ssg&#xe5;rd L, Stramer SL, Lehrer AT, Nerurkar VR, Wang WK. 2019. A high-throughput and multiplex microsphere immunoassay based on non-structural protein 1 can discriminate three flavivirus infections. PLoS Negl Trop Dis 13:e0007649. doi:10.1371/journal.pntd.0007649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0007649</ArticleId><ArticleId IdType="pmc">PMC6707547</ArticleId><ArticleId IdType="pubmed">31442225</ArticleId></ArticleIdList></Reference><Reference><Citation>Premkumar L, Collins M, Graham S, Liou GA, Lopez CA, Jadi R, Balmaseda A, Brackbill JA, Dietze R, Camacho E, De Silva AD, Giuberti C, Dos Reis HL, Singh T, Heimsath H, Weiskopf D, Sette A, Osorio JE, Permar SR, Miley MJ, Lazear HM, Harris E, de Silva AM. 2018. Development of envelope protein antigens to serologically differentiate Zika virus infection from dengue virus infection. J Clin Microbiol 56:e01504-17. doi:10.1128/JCM.01504-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01504-17</ArticleId><ArticleId IdType="pmc">PMC5824056</ArticleId><ArticleId IdType="pubmed">29263206</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao DY, Whitney MT, Davis BS, Medina FA, Munoz JL, Chang GJ. 2019. Comprehensive evaluation of differential serodiagnosis between Zika and dengue viral infections. J Clin Microbiol 57:e01506-18. doi:10.1128/JCM.01506-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01506-18</ArticleId><ArticleId IdType="pmc">PMC6425182</ArticleId><ArticleId IdType="pubmed">30541932</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockstroh A, Moges B, Barzon L, Sinigaglia A, Pal&#xf9; G, Kumbukgolla W, Schmidt-Chanasit J, Sarno M, Brites C, Moreira-Soto A, Drexler JF, Ferreira OC, Ulbert S. 2017. Specific detection of dengue and Zika virus antibodies using envelope proteins with mutations in the conserved fusion loop. Emerg Microbes Infect 6:e99. doi:10.1038/emi.2017.87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2017.87</ArticleId><ArticleId IdType="pmc">PMC5717088</ArticleId><ArticleId IdType="pubmed">29116222</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Jordan JL. 2017. Diagnosis of Zika virus infections: challenges and opportunities. J Infect Dis 216:S951&#x2013;S956. doi:10.1093/infdis/jix502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix502</ArticleId><ArticleId IdType="pmc">PMC5853979</ArticleId><ArticleId IdType="pubmed">29267922</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C-Y, Tsai W-Y, Lin S-R, Kao C-L, Hu H-P, King C-C, Wu H-C, Chang G-J, Wang W-K. 2008. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82:6631&#x2013;6643. doi:10.1128/JVI.00316-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00316-08</ArticleId><ArticleId IdType="pmc">PMC2447043</ArticleId><ArticleId IdType="pubmed">18448542</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai W-Y, Durbin A, Tsai J-J, Hsieh S-C, Whitehead S, Wang W-K. 2015. Complexity of neutralization antibodies against multiple dengue viral serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies. J Virol 89:7348&#x2013;7362. doi:10.1128/JVI.00273-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00273-15</ArticleId><ArticleId IdType="pmc">PMC4473561</ArticleId><ArticleId IdType="pubmed">25972550</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna SL, Pierson TC, Sanchez MD, Ahmed AA, Murtadha MM, Doms RW. 2005. N-linked glycosylation of West Nile virus envelope proteins influences particle assembly and infectivity. J Virol 79:13262&#x2013;13274. doi:10.1128/JVI.79.21.13262-13274.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.21.13262-13274.2005</ArticleId><ArticleId IdType="pmc">PMC1262570</ArticleId><ArticleId IdType="pubmed">16227249</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinhagen K, Probst C, Radzimski C, Schmidt-Chanasit J, Emmerich P, van Esbroeck M, Schinkel J, Grobusch MP, Goorhuis A, Warnecke JM, Lattwein E, Komorowski L, Deerberg A, Saschenbrecker S, St&#xf6;cker W, Schlumberger W. 2016. Serodiagnosis of Zika virus (ZIKV) infections by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: a multicohort study of assay performance, 2015 to 2016. Euro Surveill 21:pii=30426. doi:10.2807/1560-7917.ES.2016.21.50.30426.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2016.21.50.30426</ArticleId><ArticleId IdType="pmc">PMC5291135</ArticleId><ArticleId IdType="pubmed">28006649</ArticleId></ArticleIdList></Reference><Reference><Citation>Montoya M, Collins M, Dejnirattisai W, Katzelnick LC, Puerta-Guardo H, Jadi R, Schildhauer S, Supasa P, Vasanawathana S, Malasit P, Mongkolsapaya J, de Silva AD, Tissera H, Balmaseda A, Screaton G, de Silva AM, Harris E. 2018. Longitudinal analysis of antibody cross-neutralization following Zika virus and dengue virus infection in Asia and the Americas. J Infect Dis 218:536&#x2013;545. doi:10.1093/infdis/jiy164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiy164</ArticleId><ArticleId IdType="pmc">PMC6047418</ArticleId><ArticleId IdType="pubmed">29618091</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention, Association of Public Health Laboratories. 2014. Laboratory testing for the diagnosis of HIV infection: updated recommendations. Centers for Disease Control and Prevention, Atlanta, GA. http://stacks.cdc.gov/view/cdc/23447.</Citation></Reference><Reference><Citation>Halstead SB. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60:421&#x2013;467. doi:10.1016/s0065-3527(03)60011-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0065-3527(03)60011-4</ArticleId><ArticleId IdType="pubmed">14689700</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi E, Mason PW. 1993. Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein. J Virol 67:1672&#x2013;1675. doi:10.1128/JVI.67.3.1672-1675.1993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.67.3.1672-1675.1993</ArticleId><ArticleId IdType="pmc">PMC237541</ArticleId><ArticleId IdType="pubmed">8437237</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai WY, Hsieh SC, Lai CY, Lin HE, Nerurkar VR, Wang WK. 2012. The C-terminal helical domains of dengue virus type 4 E protein affect the expression/stability of prM protein and conformation of prM and E proteins. PLoS One 7:e52600. doi:10.1371/journal.pone.0052600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052600</ArticleId><ArticleId IdType="pmc">PMC3530441</ArticleId><ArticleId IdType="pubmed">23300717</ArticleId></ArticleIdList></Reference><Reference><Citation>Churdboonchart V, Bhamarapravati N, Peampramprecha S, Sirinavin S. 1991. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am J Trop Med Hyg 44:481&#x2013;493. doi:10.4269/ajtmh.1991.44.481.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.1991.44.481</ArticleId><ArticleId IdType="pubmed">2063952</ArticleId></ArticleIdList></Reference><Reference><Citation>Se-Thoe SY, Ng MM, Ling AE. 1999. Retrospective study of Western blot profiles in immune sera of natural dengue virus infections. J Med Virol 57:322&#x2013;330. doi:10.1002/(SICI)1096-9071(199903)57:3&lt;322::AID-JMV17&gt;3.0.CO;2-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9071(199903)57:3&lt;322::AID-JMV17&gt;3.0.CO;2-5</ArticleId><ArticleId IdType="pubmed">10022806</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdes K, Alvarez M, Pupo M, Vazquez S, Rodriguez R, Guzman MG. 2000. Human dengue antibodies against structural and nonstructural proteins. Clin Diagn Lab Immunol 7:856&#x2013;857. doi:10.1128/CDLI.7.5.856-857.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CDLI.7.5.856-857.2000</ArticleId><ArticleId IdType="pmc">PMC95972</ArticleId><ArticleId IdType="pubmed">10973471</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons G, Stone M, Busch MP. 2018. Arbovirus diagnostics: from bad to worse due to expanding dengue virus vaccination and Zika virus epidemics. Clin Infect Dis 66:1181&#x2013;1183. doi:10.1093/cid/cix972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cix972</ArticleId><ArticleId IdType="pmc">PMC6248677</ArticleId><ArticleId IdType="pubmed">29301009</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan G, Gordon A, Avil&#xe9;s W, Ortega O, Hammond SN, Elizondo D, Nu&#xf1;ez A, Coloma J, Balmaseda A, Harris E. 2009. The Nicaraguan pediatric dengue cohort study: study design, methods, use of information technology, and extension to other infectious diseases. Am J Epidemiol 170:120&#x2013;129. doi:10.1093/aje/kwp092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwp092</ArticleId><ArticleId IdType="pmc">PMC2700880</ArticleId><ArticleId IdType="pubmed">19435864</ArticleId></ArticleIdList></Reference><Reference><Citation>Narvaez F, Gutierrez G, Perez MA, Elizondo D, Nu&#xf1;ez A, Balmaseda A, Harris E. 2011. Evaluation of the Traditional and revised WHO classifications of dengue disease severity. PLoS Negl Trop Dis 5:e1397. doi:10.1371/journal.pntd.0001397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001397</ArticleId><ArticleId IdType="pmc">PMC3210746</ArticleId><ArticleId IdType="pubmed">22087348</ArticleId></ArticleIdList></Reference><Reference><Citation>Stramer SL, Fang CT, Foster GA, Wagner AG, Brodsky JP, Dodd RY. 2005. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med 353:451&#x2013;459. doi:10.1056/NEJMoa044333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa044333</ArticleId><ArticleId IdType="pubmed">16079368</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WK, Chen HL, Yang CF, Hsieh SC, Juan CC, Chang SM, Yu CC, Lin LH, Huang JH, King CC. 2006. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis 43:1023&#x2013;1030. doi:10.1086/507635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/507635</ArticleId><ArticleId IdType="pubmed">16983615</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CY, Williams KL, Wu YC, Knight S, Balmaseda A, Harris E, Wang WK. 2013. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis 7:e2451. doi:10.1371/journal.pntd.0002451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002451</ArticleId><ArticleId IdType="pmc">PMC3777924</ArticleId><ArticleId IdType="pubmed">24069496</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai JJ, Liu CK, Tsai WY, Liu LT, Tyson J, Tsai CY, Lin PC, Wang WK. 2018. Seroprevalence of dengue in two districts of Kaohsiung city after the largest dengue outbreak in Taiwan since world War II. PLoS Negl Trop Dis 12:e0006879. doi:10.1371/journal.pntd.0006879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0006879</ArticleId><ArticleId IdType="pmc">PMC6218099</ArticleId><ArticleId IdType="pubmed">30356316</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai WY, Chen HL, Tsai JJ, Dejnirattisai W, Jumnainsong A, Mongkolsapaya J, Screaton G, Crowe JE, Jr, Wang WK. 2018. Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy of dengue vaccine. J Virol 92:e00556-18. doi:10.1128/JVI.00556-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00556-18</ArticleId><ArticleId IdType="pmc">PMC6232466</ArticleId><ArticleId IdType="pubmed">30185598</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey A, Di Canzio J, Zurakowski D. 1998. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 221:35&#x2013;41. doi:10.1016/s0022-1759(98)00170-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-1759(98)00170-7</ArticleId><ArticleId IdType="pubmed">9894896</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>